Aug 29, 2023

Featuring a slide presentation and related discussion from Dr Jeremy Abramson, including the following topics:

• Long-term follow-up data with Bruton tyrosine kinase (BTK) inhibitors as monotherapy for chronic lymphocytic leukemia (CLL): The CLL12 and SEQUOIA trials (0:00)
• Extended follow-up results with venetoclax combined with anti-CD20 antibodies or a BTK inhibitor for CLL: The CLL14, MURANO and GLOW trials (5:27)
• Primary analysis of the TRANSCEND CLL 004 trial evaluating lisocabtagene maraleucel for relapsed/refractory (R/R) CLL (12:40)
• Genomic evolution and resistance to pirtobrutinib in patients with covalent BTK inhibitor-pretreated CLL in the Phase I/II BRUIN study (16:24)
• Chimeric antigen receptor (CAR) T-cell therapy data with axicabtagene ciloleucel and lisocabtagene maraleucel for R/R follicular lymphoma (FL) (18:24)
• Bispecific antibodies as treatment for R/R FL: mosunetuzumab, epcoritamab, odronextamab and TNB-486 (22:57)
• Novel treatment approaches for mantle cell lymphoma (MCL): First-line acalabrutinib/rituximab and lisocabtagene maraleucel for R/R disease (32:54)
• Updated results from studies evaluating loncastuximab tesirine, such as LOTIS-2, and CAR T-cell therapy, such as TRANSFORM and ZUMA-7, for R/R diffuse large B-cell lymphoma (39:29)
• Ongoing follow-up from pivotal trials of bispecific antibodies for large B-cell lymphomas (46:01)
• SWOG-S1826: Results from the Phase III trial evaluating nivolumab with doxorubicin/vinblastine/dacarbazine (AVD) versus brentuximab vedotin with AVD for advanced-stage classic Hodgkin lymphoma (51:48)

CME information and select publications